

20 March 2025

Osteopore enhances strategic refocus with early cessation of dental grant project

Australian-Singaporean regenerative medicine company **Osteopore Limited** (ASX: **OSX**; **Osteopore** or **the Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants – would like to advise the early cessation of its A\$18.7m clinical-industrial partnership project, first announced in December 2021¹ and in June 2024², following a strategic review.

The Company would like to emphasise that this is not a reflection of the technical viability of the project or the potential of the underlying technology. This strategic decision facilitates reallocation of resources, and aligns with the Company's near and mid-term objectives of prioritising commercialisation.

Osteopore would like to extend its sincere gratitude to its collaboration partners: the National Dental Centre Singapore (NDCS), A*STAR's Institute of Molecular and Cell Biology (IMCB), and the Singapore Institute of Manufacturing Technology (SIMTech). Their dedication, expertise and contributions have been invaluable in advancing regenerative dental solutions and we deeply appreciate their commitment to innovation and scientific excellence.

¹ ASX Announcement, "Osteopore secures A\$19m clinical-industrial partnership", 13 Dec 2021.

² ASX Announcement, "A\$18.7m Osteopore, NDCS and A*STAR project hits milestones", 6 Jun 2024.



As communicated in our recent quarterly reports, the Company has been seeking opportunities to improve cost center performance whilst streamlining expenses³. FY 2024 has seen direct sales and marketing expenses account for 5% of revenue, as compared to FY 2023 where this ratio was higher at 17%. FY 2024 has also seen a year-on-year increase in revenue by 27% and gross profit by 45%, while operating loss reduced by 41%⁴. This further demonstrates that the Company is able to operate efficiently with streamlined expenses. This approach along with the reallocation of resources following the cessation of the A\$18.7m dental grant project, will free significant resources to strengthen our market position, enhance operational capacity and drive sustainable growth, thereby delivering greater value to stakeholders.

We appreciate the ongoing support of our stakeholders and look forward to sharing further updates as we advance our strategic roadmap.

ENDS

This announcement has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr Yujing Lim

Chief Executive Officer

Osteopore Limited

E: lim_yujing@osteopore.com

Isaac Stewart

Media & Investor Relations

Purple

E: istewart@purple.au

About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across

³ Activities Report September 2024 and Appendix 4C, 31 Oct 2024.

⁴ Appendix 4E Preliminary Final Report, 28 Feb 2025.



multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement. You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement.

This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.

